Applied Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights - APLT ...

APLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Applied Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! ...

Shareholders that Lost Money on Applied Therapeutics, Inc. (APLT) Should Contact Levi & Korsinsky about Pending Class Action - APLT ...

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 18, 2025 in Applied Therapeutics, Inc. Lawsuit – APLT ...

APLT FRAUD ALERT: Applied Therapeutics Sued after Stock Drops 80% - Investors with Losses are Urged to Contact BFA Law before February 18 Class Action Deadline ...

Class Action Filed Against Applied Therapeutics, Inc. (APLT) Seeking Recovery for Investors - Contact Levi & Korsinsky ...

Applied Therapeutics, Inc. Is Being Sued For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm ...

Contact Levi & Korsinsky by February 18, 2025 Deadline to Join Class Action Against Applied Therapeutics, Inc. (APLT) ...

APLT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Applied Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! ...

Core Viewpoint - A class action securities lawsuit has been filed against Applied Therapeutics, Inc. due to alleged securities fraud affecting investors between January 3, 2024, and December 2, 2024 [1] Group 1: Case Details - On November 27, 2024, Applied Therapeutics announced it received a Complete Response Letter (CRL) from the FDA for its New Drug Application (NDA) for govorestat, indicating deficiencies in the clinical application [2] - Following the CRL announcement, the stock price of Applied Therapeutics dropped from $10.21 per share on November 26, 2024, to $8.57 on November 27, 2024, and further declined to $2.03 on November 29, 2024, and $1.75 on December 2, 2024, marking a total decline of over 80% [2] - After disclosing a "warning letter" from the FDA on December 2, 2024, regarding clinical trial issues, the stock price fell further to $1.69 on December 3, 2024, and continued to decline to $1.38 on December 4, 2024, and $1.29 on December 5, 2024 [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until February 18, 2025, to request the Court to appoint them as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]